Ocuphire Pharma Investor Update

3 Agenda and Participants Second Phase 3 RM Trial Topline Readout as Planned in 1Q22 ● ● ● Highlights and Overview Topline MIRA-3 Phase 3 Clinical Trial Results for Nyxol in Reversal of Mydriasis (RM) Reversal of Mydriasis Market Opportunity Upcoming Milestones Q&A Participants Mina Sooch, MBA, President and CEO Jay Pepose, MD, PhD, Medical Advisory Board and Board Member Mitch Brigell, PhD, Head of Clinical Development Susan Benton, MBA, Corporate Board Member Bindu Manne, Head of Market Development and Commercialization Charlie Hoffmann, MBA, VP of Corporate Development and Operations Amy Rabourn, MAcc, VP of Finance Ocuphire PHARMA

View entire presentation